Caixa Innvierte BioMed II

MedLumics, a company owned by “la Caixa” and Ysios Capital, closes a financing round of 34.4 million euros

• Medlumics has closed a round of financing round of 34,4 million euros to bring their main product into the market, AblaView, an atrial fibrillation treatment in the field of cardiac arrhythmias.
• Medlumics is a company dedicated to medical technology for the treatment of cardiac diseases, with products based on photonic energy.
• Caixa Capital Risc and Ysios Capital invested in Medlumics in 2012 to support the company in its development.
• This has been the largest round in the history of the medical technology industry in Spain, and one of the largest in Europe.

| Read more |

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

MIN-102, a differentiated PPAR agonist, targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with a high unmet medical need

– Trial will assess pharmacokinetics, safety and tolerability of MIN-102 after administration of single and multiple ascending doses in healthy volunteers.

| Read more |

(Español) Minoryx Therapeutics nombra al Dr. Uwe Meya como Director Médico

(Español) El Dr. Meya, especialista en trastornos neurológicos, dirigirá el desarrollo clínico del principal candidato de Minoryx, el MIN-102, para la X-ALD.

| Read more |

Stat Diagnostica announces 25 Million Euros in Series C Financing

– Led by new investor Gilde Healthcare , the financing round al so drew participation from existing investors , including Kurma Partners ; Ysios Capital ; Idinvest Partners ; Boehringer Ingelheim Venture Fund ; Caixa Capital Risc ; and Axis. “

| Read more |

”la Caixa” leads an investment round in Inbiomotion with the participation of Ysios Capital

• The company concludes a 2.2 million Euro round led by ”la Caixa” through Caixa Capital Risc. Also participating in the operation were Ysios Capital, which led the first investment round for the company in 2012, and Fundación Vila Casas, which were already shareholders in the spin-off.

• Inbiomotion develops diagnostic products for predicting risks that cancer patients may suffer bone metastasis.

• The capital increase is intended to complete the clinical and regulatory development of the company’s products in the next 2 years.

• The target markets for Inbiomotion are breast cancer and prostate cancer, where bone metastasis is most common.

| Read more |